REG - Haleon PLC - Transaction in Own Shares

HALEONAnnouncement

26/09/2024 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ8896Fa&default-theme=true

RNS Number : 8896F  Haleon PLC  26 September 2024

 

 

 

Haleon plc: Transaction in own shares

 

26 September 2024: Haleon plc (the "Company" or "Haleon") today announces the
purchase of the following number of ordinary shares of £0.01 each in the
Company (the "Shares") for cancellation under its share buyback programme
announced on 1 August 2024 (the "Buyback Programme").

 

 Date of purchase:                                  26 September 2024
 Number of Shares purchased:                        508,000
 Highest price paid per Share (p):                  394.0000
 Lowest price paid per Share (p):                   387.9000
 Volume weighted average price paid per Share (p):  390.3223

 

Following the settlement of the above, the Company's registered share capital
consists of 9,113,887,197 ordinary shares. This figure may be used by
shareholders to determine if they are required to notify their interest, or a
change to their interest, in Haleon under the FCA's Disclosure Guidance and
Transparency Rules.

 

In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/8896F_1-2024-9-26.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/8896F_1-2024-9-26.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Sonya Ghobrial                          +44 7392 784784                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Gemma Thomas                         +44 7985 175048
 Emma White                              +44 7823 523562
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSQQLFLZKLZBBD